Sugi Predict

Sugi Predict / Compounds / SCHEMBL2490765

SCHEMBL2490765

SCHEMBL2490765

CC(C)(C)OC(=O)COCC1CCCN1C(=O)OC(C)(C)C

nearest known ligand 0.45

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ ALOX5AP P20292 1/20 0.41
▸ FEN1 P39748 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.40
▸ PDE8B O95263 1/20 0.39
▸ OPRD1 P41143 1/20 0.39
▸ ATM Q13315 2/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ TSHR P16473 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3771067 1.00 HSD17B10 (0.43) HSD17B10SMN1; SMN2ALOX5APFEN1ALDH1A1
SCHEMBL29039261 1.00 HSD17B10 (0.43) HSD17B10SMN1; SMN2ALOX5APFEN1ALDH1A1
SCHEMBL3763846 0.96 PDE8B (0.43) HSD17B10SMN1; SMN2ALOX5APFEN1ALDH1A1
SCHEMBL5160976 0.92 SMN1; SMN2 (0.37) HSD17B10SMN1; SMN2ALOX5APFEN1ALDH1A1
SCHEMBL3781269 0.92 HSD17B10 (0.36) HSD17B10SMN1; SMN2ALDH1A1ATM
SCHEMBL3781276 0.92 HSD17B10 (0.36) HSD17B10SMN1; SMN2ALDH1A1ATM
SCHEMBL6318180 0.90 KMT2A (0.43) HSD17B10SMN1; SMN2ALOX5APFEN1ALDH1A1
SCHEMBL2566481 0.89 HSD17B10 (0.38) HSD17B10SMN1; SMN2ALOX5APFEN1ALDH1A1
SCHEMBL2568345 0.89 HSD17B10 (0.46) HSD17B10SMN1; SMN2ALOX5APFEN1ALDH1A1
SCHEMBL3774461 0.89 HSD17B10 (0.46) HSD17B10SMN1; SMN2ALOX5APFEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116234802-A Quinoline CGAS antagonist compounds 免疫传感器治疗股份有限公司 2023-06-06 — — CN disclosed
US-20180362583-A1 INTEGRIN INTERACTION INHIBITORS FOR THE TREATMENT OF CANCER H LEE MOFFITT CANCER CT & RES (US) 2018-12-20 — — US disclosed
US-10059740-B2 Integrin interaction inhibitors for the treatment of cancer H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2018-08-28 — — US disclosed
US-20160257712-A1 INTEGRIN INTERACTION INHIBITORS FOR THE TREATMENT OF CANCER H LEE MOFFITT CANCER CT & RES (US) 2016-09-08 — — US disclosed
US-8853149-B2 Integrin interaction inhibitors for the treatment of cancer H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2014-10-07 — — US disclosed
WO-2013170066-A1 PEPTIDES FOR THE TREATMENT OF CANCER H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) 2013-11-14 — — WO disclosed
US-8435978-B2 Substituted sulfonamide compounds GRUENENTHAL GMBH (DE) 2013-05-07 — — US disclosed
US-8435978-B2 Substituted sulfonamide compounds GRUENENTHAL GMBH (DE) 2013-05-07 — — US disclosed
US-20130065837-A1 INTEGRIN INTERACTION INHIBITORS FOR THE TREATMENT OF CANCER UNIVERSITY OF SOUTH FLORIDA (US) 2013-03-14 — — US disclosed
EP-2547693-A2 INTEGRIN INTERACTION INHIBITORS FOR THE TREATMENT OF CANCER H. Lee Moffitt Cancer Center & Research Institute (US) 2013-01-23 — — EP disclosed
WO-2011115688-A2 INTEGRIN INTERACTION INHIBITORS FOR THE TREATMENT OF CANCER H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) 2011-09-22 — — WO disclosed
US-20100324009-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2010-12-23 — — US disclosed
US-20100324009-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2010-12-23 — — US disclosed
US-20100317644-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2010-12-16 — — US disclosed
US-20100317644-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2010-12-16 — — US disclosed
US-20080153843-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS GRUENENTHAL GMBH (DE) 2008-06-26 — — US disclosed
US-20080153843-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS GRUENENTHAL GMBH (DE) 2008-06-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180362583-A1 INTEGRIN INTERACTION INHIBITORS FOR THE TREATMENT OF CANCER ITGB1, ITGB7, ITGA2B HSD17B10 4504/4885SMN1; SMN2 3332/4885ALOX5AP 4571/4885
US-20130065837-A1 INTEGRIN INTERACTION INHIBITORS FOR THE TREATMENT OF CANCER ITGB1, ITGB7, ITGA2B HSD17B10 4504/4885SMN1; SMN2 3332/4885ALOX5AP 4571/4885
US-20100317644-A1 Substituted Sulfonamide Compounds SULT2A1, STS, SULT1A1 HSD17B10 3104/4885SMN1; SMN2 45/4885ALOX5AP 1071/4885
US-20100324009-A1 Substituted Sulfonamide Compounds SULT2A1, STS, SULT1A1 HSD17B10 3104/4885SMN1; SMN2 45/4885ALOX5AP 1071/4885
US-10059740-B2 Integrin interaction inhibitors for the treatment of cancer ITGB1, ITGB7, ITGA2B HSD17B10 4504/4885SMN1; SMN2 3332/4885ALOX5AP 4571/4885
US-20080153843-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS SULT2A1, STS, SULT1A1 HSD17B10 3104/4885SMN1; SMN2 45/4885ALOX5AP 1071/4885
US-20160257712-A1 INTEGRIN INTERACTION INHIBITORS FOR THE TREATMENT OF CANCER ITGB1, ITGB7, ITGA2B HSD17B10 4504/4885SMN1; SMN2 3332/4885ALOX5AP 4571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.